Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 30 Issue 10, October 2012

Stones traversing Death Valley in California; innovations in biomedicine often stall or die traversing the funding lacuna between basic research and product development (the so-called Valley of Death). Credit: Georg Gerster/Photo Researchers, Inc.

Volume 30 Issue 10

Subscribe

Editorial

  • The biotech investment community needs to look beyond the existing pools of funding and talent to galvanize biomedical innovation.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Data Page

Top of page ⤴

Bioentrepreneur

Top of page ⤴

Correspondence

Top of page ⤴

Commentary

Top of page ⤴

Feature

  • There was a time when academia viewed industry simply as a cash cow; today, it's all about sharing common goals and mutual respect for cultural differences.

    • Beth Schachter
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

  • Transplanting donor cells into lymph nodes regenerates liver, pancreas and thymus function in mice.

    • Johannes L Zakrzewski
    • Andrea Z Tuckett
    • Marcel R M van den Brink
    News & Views

  • Metagenomics reveals the identities of the microorganisms that make up the endophytic and rhizosphere microbiomes of the model plant Arabidopsis thaliana.

    • Penny R Hirsch
    • Tim H Mauchline
    News & Views
Top of page ⤴

Profile

Top of page ⤴

Perspective

  • The authors propose that the increasing risk of biopharma investing can be reduced through megafunds that support many biomedical programs and attract investment from large institutions such as pension funds.

    • Jose-Maria Fernandez
    • Roger M Stein
    • Andrew W Lo
    Perspective
Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Careers and Recruitment

  • China's recent R&D investment has resulted in a growth in research capacity and personnel, particularly in the agbiotech sector.

    • Jikun Huang
    • Ruifa Hu
    • Xiaobing Wang
    Careers and Recruitment

  • Careers and Recruitment
Top of page ⤴

In This Issue

Top of page ⤴

Focus

  • The present system for commercializing biomedical research remains woefully inefficient and underpowered. This issue of Nature Biotechnologycollects several articles that describe alternatives to current pathways for clinical translation of academic discovery.

    Focus
Top of page ⤴

Search

Advanced search

Quick links